Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

676
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
676
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

2.6K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hierarchical Studies in TRAP2 Mice Demonstrate that Neuronal Activation and Mitochondrial Networks Integration Constitute the Key Mechanism Underlying Painful Syncope.

Neuroscience bulletin·2026
Same author

Rare sphenoid dural arteriovenous fistula treated with microsurgery: illustrative case.

Journal of neurosurgery. Case lessons·2026
Same author

A wide-necked saccular aneurysm of the middle cerebral artery bifurcation with neck atherosclerosis mimicking a fusiform aneurysm: illustrative case.

Journal of neurosurgery. Case lessons·2026
Same author

The CircRNA/miRNA axis in breast cancer: From molecular mechanisms to clinical translation.

Pharmacology & therapeutics·2026
Same author

Deep learning-based spatiotemporal estimation of lesion changes for patient-level assessment of breast cancer lung metastases on longitudinal CT.

NPJ precision oncology·2026
Same author

Monoclonal antibodies targeting PCDH7 inhibit tumor growth and enhance immune responses in <i>KRAS</i>-mutant non-small cell lung cancer.

Science advances·2026

Related Experiment Video

Updated: Jun 12, 2025

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
05:07

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

6.6K

Design, synthesis and structure-activity relationship studies of novel macrocyclic 2,4-diaminopyrimidines as HPK1

Feifei Wu1, Jiaqi Sun2, Mingyang Xu3

  • 1Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, #555 Zu Chong Zhi Road, Shanghai 201203, China; University of Chinese Academy of Science, 19 Yuquan Road, Beijing 110039, China.

Bioorganic & Medicinal Chemistry
|June 10, 2025
PubMed
Summary
This summary is machine-generated.

Researchers developed novel macrocyclic compounds targeting Hematopoietic progenitor kinase 1 (HPK1) for cancer immunotherapy. Compound 21 shows potent HPK1 inhibition, enhancing T cell activity and offering a promising lead for new cancer treatments.

Keywords:
Cancer immunotherapyHPK1InhibitorsKinaseMacrocycle

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

454
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.5K

Related Experiment Videos

Last Updated: Jun 12, 2025

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
05:07

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

6.6K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

454
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.5K

Area of Science:

  • Medicinal Chemistry
  • Immunology
  • Oncology

Background:

  • Hematopoietic progenitor kinase 1 (HPK1) is a critical negative regulator of T cell receptor signaling.
  • HPK1 is a potential therapeutic target for enhancing anti-cancer immune responses.
  • No small-molecule HPK1 inhibitors have yet received regulatory approval for cancer treatment.

Purpose of the Study:

  • To design and synthesize novel macrocyclic 2,4-diaminopyrimidine derivatives as inhibitors of HPK1.
  • To evaluate the inhibitory potency and downstream effects of the synthesized compounds in T cells.
  • To explore macrocyclization as a strategy for developing innovative HPK1 inhibitor scaffolds.

Main Methods:

  • Synthesis of a novel series of macrocyclic 2,4-diaminopyrimidine derivatives.
  • Biochemical assay (ADP-Glo) to determine HPK1 inhibitory activity (IC50).
  • Cell-based assays using human Jurkat T cells to assess inhibition of SLP76 phosphorylation and IL-2 secretion.

Main Results:

  • The representative compound 21 demonstrated potent HPK1 inhibition with an IC50 of 1.0 nM.
  • Compound 21 effectively suppressed phosphorylation of the downstream signaling protein SLP76.
  • Treatment with compound 21 led to enhanced interleukin-2 (IL-2) secretion in Jurkat T cells.

Conclusions:

  • Macrocyclization is a validated strategy for creating innovative scaffolds for HPK1 inhibitors.
  • Compound 21 represents a structurally novel and potent lead compound for HPK1 inhibitor development.
  • These findings support the advancement of HPK1 inhibitors for cancer immunotherapy applications.